SINGAPORE – Media OutReach – 15 December 2021 – ARISTA Biotech Pte Ltd (“ARISTA”), manufacturer of COVID-19 antigen & antibody diagnostics, confirms that its COVID-19 antigen rapid test, which tests for the presence of SARS-CoV-2 virus in clinical specimens, is able to detect the recently identified B.1.1.529 (Omicron) variant.
On 26th November 2021, the World Health Organization (WHO) announced and designated variant B.1.1529 named Omicron, a newly identified variant first identified in Botswana and South Africa, as a Variant of Concern. Early indication suggested this variant may have higher transmissibility and has already spread to over 30 countries in an accelerated manner.
Sequence study of the Omicron variant confirmed that it harbors more than 30 mutations across its genome with the majority of mutations in the Spike protein. The Omicron variant possesses three replacement and one deletion mutations in the N-protein compared to the original viral strain (Table 1).
https://aristabio.com
#ARISTABiotech
The issuer is solely responsible for the content of this announcement.
